OTC labeling comprehension "real use" data is lacking, NDAC members agree.
This article was originally published in The Tan Sheet
Executive Summary
OTC LABELING COMPREHENSION "REAL USE" DATA IS LACKING, NDAC members agreed at a Sept. 29 meeting on labeling issues. Following a public hearing covering all aspects of OTC label comprehension, from pictograms to type size to order of information, Nonprescription Drugs Advisory Committee member Eric Brass, MD/PhD, Harbor-UCLA Medical Center, remarked that "what is very striking is the lack of comprehensive data on the real use of these drugs...in a truly representative population" and setting.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning